Clinical Trials are the Backbone of the Consortium


Currently enrolling trials

  • UCHMC1401: A Phase II Study of Punctual, Cyclic, and Intensive Chemotherapy with Liposomal Cytarabine (Depocyt®) CNS Prophylaxis for Adults With Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

o   Participating Centers: UCSD (Primary), UCLA, UCSF, UCD

o   https://clinicaltrials.gov/ct2/show/NCT02043587?term=Depocyt&rank=7

 

  • UCHMC1502: A Phase I/II Study of PiC-D (Ixazomib in Combination with Pomalidomide, Clarithromycin and Dexamethasone) in Patients with Double Refractory Multiple Myeloma

o   Participating Centers: UCD (Primary), UCSD, UCI

o   https://clinicaltrials.gov/ct2/show/NCT02542657?term=Tuscano&rank=4

 

  • ·UCHMC1503: Phase 1b Trial of the Combination of Ibrutinib and Azacitidine for the Treatment of Higher Risk Myelodysplastic Syndromes in Previously Treated Patients or in Untreated Patients Unfit for or Who Refuse Intense Therapy(UCDCC#256 [PCYC#20051])

o   Participating Centers: UCD (Primary), UCSD, UCSF

o   https://clinicaltrials.gov/ct2/show/NCT02553941?term=brian+jonas&rank=2

 

  • ·UCHMC1504: A Phase I/II study of blinatumomab in combination with pembrolizumab (MK-3475) for adults with relapsed or refractory B-lineage acute lymphoblastic leukemiawith high bone marrow lymphoblast count: A University of California Hematologic Malignancies Consortium

o   Participating Centers: UCSD (Primary), UCI, UCSF

o   https://clinicaltrials.gov/ct2/show/NCT03160079?term=wieduwilt&draw=1&rank=1

 

  • UCHMC1606: A Phase 2 clinical trial to evaluate obinutuzumab with high-dose ibrutinib for the treatment of patients with chronic lymphocytic leukemia with progressive disease on single agent Ibrutinib

o   Participating Centers: UCSD (Primary), UCI

o   https://clinicaltrials.gov/ct2/show/NCT02611908?term=Choi+ibrutinib&rank=1

·       

Future Trials

Multiple Trials Currently under Development- More Information will be provided as it becomes available.